Literature DB >> 25312689

Comparison of the effect of 'metabolically healthy but obese' and 'metabolically abnormal but not obese' phenotypes on development of diabetes and cardiovascular disease in Chinese.

Deng Luo1, Fang Liu, Xiaowen Li, Dechao Yin, Ziwei Lin, Hui Liu, Xuhong Hou, Chen Wang, Weiping Jia.   

Abstract

The present study was designed to determine the prevalence of 'metabolically healthy but obese' (MHO) and 'metabolically abnormal but not obese' (MANO) phenotypes in Chinese population, and to investigate the association of these two phenotypes with the risk of diabetes and cardiovascular disease (CVD). A total of 2,764 subjects aged 30-90 were followed up over a mean period of 43.80 ± 11.25 months. The metabolic syndrome was defined according to the joint committee for developing Chinese guidelines on prevention and treatment of dyslipidemia in adults. Subjects with body fat percentage (BF %) >25 % for men or BF % >35 % for women were defined as being obese. The proportion of MHO and MANO phenotypes were 22.9, 7.6 % in men, and 26.2, 6.0 % in women, respectively. The MANO phenotype was associated with increased risk for diabetes both in men [hazard ratios (HR): 4.44 (1.21-16.26)] and women [HR: 8.68 (2.87-24.96)] after adjustment of age, serum total cholesterol (TC), triglycerides (TG), and family history of diabetes. This association held for CVD in women [HR: 2.87 (1.44-5.73)], but not in men after adjustment of age, serum TC, TG, and family history of CVD. No association was observed between the MHO phenotype and incident diabetes or CVD. MHO and MANO phenotypes are common in Chinese population. Metabolic risk factors appeared to play a more important role in the development of diabetes and CVD than body fat alone.

Entities:  

Mesh:

Year:  2014        PMID: 25312689     DOI: 10.1007/s12020-014-0444-2

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  49 in total

Review 1.  Characteristics of obesity and its related disorders in China.

Authors:  Wei-Ping Jia; Chen Wang; Shan Jiang; Jie-Min Pan
Journal:  Biomed Environ Sci       Date:  2010-02       Impact factor: 3.118

2.  Phenotypic characteristics associated with insulin resistance in metabolically obese but normal-weight young women.

Authors:  R V Dvorak; W F DeNino; P A Ades; E T Poehlman
Journal:  Diabetes       Date:  1999-11       Impact factor: 9.461

3.  Comparison of body mass index with body fat percentage in the evaluation of obesity in Chinese.

Authors:  Chen Wang; Xu-Hong Hou; Ming-Liang Zhang; Yu-Qian Bao; Yu-Hua Zou; Wen-Hong Zhong; Kun-San Xiang; Wei-Ping Jia
Journal:  Biomed Environ Sci       Date:  2010-06       Impact factor: 3.118

4.  Metabolic syndrome in normal-weight Americans: new definition of the metabolically obese, normal-weight individual.

Authors:  Marie-Pierre St-Onge; Ian Janssen; Steven B Heymsfield
Journal:  Diabetes Care       Date:  2004-09       Impact factor: 19.112

Review 5.  The role of hepatokines in metabolism.

Authors:  Norbert Stefan; Hans-Ulrich Häring
Journal:  Nat Rev Endocrinol       Date:  2013-01-22       Impact factor: 43.330

6.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

Review 7.  Metabolic and body composition factors in subgroups of obesity: what do we know?

Authors:  Antony D Karelis; David H St-Pierre; Florence Conus; Remi Rabasa-Lhoret; Eric T Poehlman
Journal:  J Clin Endocrinol Metab       Date:  2004-06       Impact factor: 5.958

8.  Association of serum retinol-binding protein 4 and visceral adiposity in Chinese subjects with and without type 2 diabetes.

Authors:  Weiping Jia; Haiya Wu; Yuqian Bao; Chen Wang; Junxi Lu; Jiehua Zhu; Kunsan Xiang
Journal:  J Clin Endocrinol Metab       Date:  2007-06-05       Impact factor: 5.958

9.  Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.

Authors:  E Bonora; S Kiechl; J Willeit; F Oberhollenzer; G Egger; G Targher; M Alberiche; R C Bonadonna; M Muggeo
Journal:  Diabetes       Date:  1998-10       Impact factor: 9.461

Review 10.  Beyond BMI: The "Metabolically healthy obese" phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality -- a systematic review.

Authors:  Lara L Roberson; Ehimen C Aneni; Wasim Maziak; Arthur Agatston; Theodore Feldman; Maribeth Rouseff; Thinh Tran; Michael J Blaha; Raul D Santos; Andrei Sposito; Mouaz H Al-Mallah; Ron Blankstein; Matthew J Budoff; Khurram Nasir
Journal:  BMC Public Health       Date:  2014-01-08       Impact factor: 3.295

View more
  10 in total

1.  The long-term prognosis of heart diseases for different metabolic phenotypes: a systematic review and meta-analysis of prospective cohort studies.

Authors:  Atieh Mirzababaei; Kurosh Djafarian; Hadis Mozafari; Sakineh Shab-Bidar
Journal:  Endocrine       Date:  2019-01-22       Impact factor: 3.633

2.  Cardiometabolic index: a new tool for screening the metabolically obese normal weight phenotype.

Authors:  X Liu; Q Wu; G Yan; J Duan; Z Chen; P Yang; N L Bragazzi; Y Lu; H Yuan
Journal:  J Endocrinol Invest       Date:  2020-09-09       Impact factor: 4.256

3.  Estimation of risk for diabetes according to the metabolically healthy status stratified by degree of obesity in Korean men.

Authors:  Jae-Hong Ryoo; Sung Keun Park; Sungmin Ye; Joong-Myung Choi; Chang-Mo Oh; Sun Yong Kim; Ju-Young Shin; Jai Hyung Park; Hyun Pyo Hong; Taeg Su Ko
Journal:  Endocrine       Date:  2015-05-29       Impact factor: 3.633

4.  Visceral adiposity index is strongly associated with hyperuricemia independently of metabolic health and obesity phenotypes.

Authors:  Huimin Dong; Yang Xu; Xiuzhi Zhang; Simiao Tian
Journal:  Sci Rep       Date:  2017-08-18       Impact factor: 4.379

5.  Association between Indices of Body Composition and Abnormal Metabolic Phenotype in Normal-Weight Chinese Adults.

Authors:  Lili Xia; Fen Dong; Haiying Gong; Guodong Xu; Ke Wang; Fen Liu; Li Pan; Ling Zhang; Yuxiang Yan; Herbert Gaisano; Yan He; Guangliang Shan
Journal:  Int J Environ Res Public Health       Date:  2017-04-07       Impact factor: 3.390

6.  Effect of Metabolic Health and Obesity Phenotype on Risk of Diabetes Mellitus: A Population-Based Longitudinal Study.

Authors:  Xiaoyue Zhu; Jingyao Hu; Haijian Guo; Dakang Ji; Defu Yuan; Mingma Li; Tao Yan; Chenghao Xue; Haonan Ma; Xu Zhou; Yuxiang Liu; You Li; Kaicheng Sun; Yu Liu; Zilin Sun; Bei Wang
Journal:  Diabetes Metab Syndr Obes       Date:  2021-08-05       Impact factor: 3.168

7.  Short-Term Changes in Metabolically Healthy Overweight/Obesity Status Impact the Susceptibility to Type 2 Diabetes in Chinese Adults.

Authors:  Jie Min; Xiang Hu; Jiaoyue Zhang; Tianshu Zeng; Ying Wang; Shenghua Tian; Geng Liu; Xueyu Zhong; Kangli Qiu; Miaomiao Peng; Lulu Chen
Journal:  Diabetes Metab Syndr Obes       Date:  2021-06-09       Impact factor: 3.168

Review 8.  Risk of type 2 diabetes in metabolically healthy people in different categories of body mass index: an updated network meta-analysis of prospective cohort studies.

Authors:  Somayeh Tajik; Atieh Mirzababaei; Ehsan Ghaedi; Hamed Kord-Varkaneh; Khadijeh Mirzaei
Journal:  J Cardiovasc Thorac Res       Date:  2019-10-24

9.  Metabolically healthy obesity, transition to unhealthy phenotypes, and type 2 diabetes in 0.5 million Chinese adults: the China Kadoorie Biobank.

Authors:  Zimin Song; Meng Gao; Jun Lv; Canqing Yu; Yu Guo; Zheng Bian; Yuxia Wei; Ling Yang; Huaidong Du; Yiping Chen; Jianqiang Zhang; Jvying Yao; Junshi Chen; Zhengming Chen; Tao Huang; Liming Li
Journal:  Eur J Endocrinol       Date:  2022-01-06       Impact factor: 6.558

Review 10.  Metabolic Obesity in People with Normal Body Weight (MONW)-Review of Diagnostic Criteria.

Authors:  Waldemar Pluta; Wioleta Dudzińska; Anna Lubkowska
Journal:  Int J Environ Res Public Health       Date:  2022-01-06       Impact factor: 3.390

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.